By selecting the Yes option, leaving Amgen.com.sg option you understand that you are leaving the corporate page of Amgen Singapore and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Singapore is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Singapore. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen's drugs target diseases that are serious and typically have limited treatment options.
With a presence in more than 100 countries, every year we reach millions of patients around the world.
At Amgen we take advantage of the full potential of biotechnology to collaborate and provide new tools for clinical practice. In Singapore, we focus on the following therapeutic areas:Cardiovascular disease is one of the top causes of morbidity and mortality in Singapore. Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease.
In general medicine, Amgen is a leader in bone health with more than 20 years of osteoporosis research experience and is committed to combating this disease to help people at high risk for fracture reduce their risk of a first and subsequent fracture.
Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological diseases, such as colorectal cancer, leukemia and multiple myeloma.
Amgen developed medicines in the field of inflammation, and we are currently discovering innovative molecules to treat chronic inflammatory diseases. Some of the conditions to which we provide solutions are for autoimmune pathologies such as rheumatoid arthritis and psoriasis, which affect thousands of patients in Singapore.
For information on the drugs that are in development, we invite you to visit our pipeline